Identifying genetic differences between bipolar disorder and major depression through multiple genome-wide association analyses

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Bipolar Disorder Working Group of the Psychiatric Genomics Consortium - (Autor:in)
  • Stephan Ripke - , Charité – Universitätsmedizin Berlin, Broad Institute of Harvard University and MIT, Deutsches Zentrum für Psychische Gesundheit (DZPG) (Autor:in)
  • Loes M. Olde Loohuis - , University of California at Irvine, University of California at Los Angeles (Autor:in)
  • Klinik und Poliklinik für Psychiatrie und Psychotherapie
  • Universität Kopenhagen
  • King's College London (KCL)
  • South London and Maudsley NHS Foundation Trust
  • Ludwig-Maximilians-Universität München (LMU)
  • University of New South Wales
  • University of Michigan Medicine
  • Rutgers - The State University of New Jersey, New Brunswick
  • University of Michigan, Ann Arbor
  • Janssen Pharmaceutica NV
  • Cardiff University
  • University of Gothenburg
  • Max Planck Institute of Psychiatry
  • Massachusetts General Hospital
  • Ernst-Moritz-Arndt-Universität Greifswald
  • Johns Hopkins Medicine
  • Columbia University
  • National Cancer Institute (NCI)
  • Mayo Clinic Rochester, MN
  • Universitätsklinikum Frankfurt
  • Universität Heidelberg
  • Icahn School of Medicine at Mount Sinai
  • Utrecht University
  • University of Worcester
  • Queensland Institute of Medical Research
  • Stanford University

Abstract

Background Accurate diagnosis of bipolar disorder (BPD) is difficult in clinical practice, with an average delay between symptom onset and diagnosis of about 7 years. A depressive episode often precedes the first manic episode, making it difficult to distinguish BPD from unipolar major depressive disorder (MDD). Aims We use genome-wide association analyses (GWAS) to identify differential genetic factors and to develop predictors based on polygenic risk scores (PRS) that may aid early differential diagnosis. Method Based on individual genotypes from case-control cohorts of BPD and MDD shared through the Psychiatric Genomics Consortium, we compile case-case-control cohorts, applying a careful quality control procedure. In a resulting cohort of 51 149 individuals (15 532 BPD patients, 12 920 MDD patients and 22 697 controls), we perform a variety of GWAS and PRS analyses. Results Although our GWAS is not well powered to identify genome-wide significant loci, we find significant chip heritability and demonstrate the ability of the resulting PRS to distinguish BPD from MDD, including BPD cases with depressive onset (BPD-D). We replicate our PRS findings in an independent Danish cohort (iPSYCH 2015, N = 25 966). We observe strong genetic correlation between our case-case GWAS and that of case-control BPD. Conclusions We find that MDD and BPD, including BPD-D are genetically distinct. Our findings support that controls, MDD and BPD patients primarily lie on a continuum of genetic risk. Future studies with larger and richer samples will likely yield a better understanding of these findings and enable the development of better genetic predictors distinguishing BPD and, importantly, BPD-D from MDD.

Details

OriginalspracheEnglisch
Seiten (von - bis)79-90
Seitenumfang12
FachzeitschriftBritish journal of psychiatry
Jahrgang226
Ausgabenummer2
PublikationsstatusVeröffentlicht - 1 Feb. 2025
Peer-Review-StatusJa

Externe IDs

PubMed 39806801
ORCID /0000-0002-2666-859X/work/205336376

Schlagworte

Ziele für nachhaltige Entwicklung

Schlagwörter

  • Bipolar disorder, early differential diagnosis, genome-wide association analysis, major depressive disorder, polygenic risk scoring